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Abstract
Objective Corneal collagen cross-linking with riboflavin and UV-A (CXL) decreases
corneal oedema and increases visual acuity in human patients with bullous keratopa-
thy. Presumed mechanisms are an increase in collagen packing density and a reduction
in stromal swelling pressure. We present two cases in which CXL was used to treat
bullous keratopathy in dogs.
Procedures Four eyes of two dogs with painful bullous keratopathy-induced corneal
erosions that were resistant to prior therapy were treated with CXL. Both corneas of
the second patient were dehydrated to  400 lm corneal thickness using topical 70%
glycerol solution immediately prior to CXL. Follow-up included slit-lamp examina-
tion, fluorescein staining and photographic documentation in both cases and high-
resolution ultrasound examination in the second patient.
Results All four eyes were comfortable and fluorescein negative at 1-week post-CXL
and remained so for the rest of the follow-up period (17.5 months for case 1 and
6 months for case 2). The owner of the first patient reported a less oedematous cornea
and improvement in vision that lasted for 6 months. Despite a reported lack of
improvement in vision in the second patient, corneal thickness initially decreased, but
was back at baseline thickness at the 4-month recheck.
Conclusions Similar to humans, CXL might become a useful treatment option for bul-
lous keratopathy-induced therapy-resistant corneal erosions in dogs. Patient comfort
was greatly improved, but corneal thickness decrease was not as long-lasting as
reported for humans. The presently used protocols might need modification to fit the
dog cornea.
Key Words: bullous keratopathy, cornea, corneal collagen cross-linking, dog,
endothelial decompensation, oedema
INTRODUCTION
Corneal collagen cross-linking (CXL) is based on the
exposure of the photosensitizer riboflavin (Vitamin B2) to
UV-A light with a wavelength at the riboflavin absorption
peak of 370 nm. This results in a free oxygen radical-
driven photopolymerization process introducing additional
covalent cross-links within collagen fibres and in the
proteoglycan–glycosaminoglycan ground substance of the
corneal stroma up to a depth of 300 lm.1,2 The result is
an increase in the biomechanical and biochemical stability
of the cornea, an increase in collagen packing density and
a reduction in the swelling tendency of the glycosamino-
glycan-rich hydrophilic ground substance of the cornea.
Reactive oxygen species (ROS)-induced damage to cells
and reduction in microorganisms in the irradiated area has
been described as well.3–8
After CXL was introduced for the treatment of progres-
sive keratoconus in humans,9 new indications for the clinical
use of CXL emerged rapidly, including the treatment of
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melting keratitis, Fuchs’ dystrophy and bullous keratopa-
thy.10,11 Melting keratitis and bullous keratopathy are two
interesting indications for the use of CXL in veterinary
medicine, as these diseases are potentially blinding and can
be difficult to control both medically and surgically.12 The
effective use of CXL for the treatment of melting keratitis
in dogs, cats and horses was recently reported.13–16
Various congenital and acquired diseases including
breed-related endothelial dystrophy, iris-to-cornea persis-
tent pupillary membranes, trauma (both surgical and non-
surgical), anterior uveitis/endotheliitis, glaucoma, toxic
damage to the endothelium, age-related endothelial
degeneration and melting keratitis can cause functional
decompensation of the corneal endothelium and result in
bullous keratopathy.12 Pain and discomfort are caused by
the recurrent or nonhealing corneal erosions that occur
with bullous keratopathy. The dense corneal oedema
results in significant loss of vision and even blindness in
severe cases. Topical application of hypertonic solutions
and ointments can decrease the extent of epithelial
oedema and bullae formation, but typically does not sig-
nificantly decrease the extent of the stromal oedema and
opacification. The frequent necessary application and local
irritation can limit the usefulness of topical hypertonic sal-
ine treatment.12 More invasive treatments including ther-
mokeratoplasty 17 and 360˚ conjunctival flap (Gunderson
flap) placement can be used successfully to treat the epi-
thelial defects, but these treatments further decrease cor-
neal transparency.12 Partial coverage of the corneal surface
with a thin conjunctival flap can function as a drainage
sink for the oedematous fluid in the stroma. This has been
observed to subjectively increase corneal transparency (P.
Bedford, personal communication; I. Allgoewer personal
communication); however, the duration of this effect is
unknown.
Corneal collagen cross-linking with riboflavin and
UV-A (CXL) decreases corneal oedema and increases
visual acuity in human patients with bullous keratopathy.11
Presumed mechanisms are an increase in collagen packing
density and a reduction in the swelling tendency of the
glycosaminoglycan-rich hydrophilic ground substance of
the cornea.3 The objective of this case report was to eval-
uate the effectiveness of CXL for the treatment of bullous
keratopathy in dogs.
METHODS
Four eyes of two dogs with a two-month history of persis-
tent corneal erosions as a result of bullous keratopathy
were treated with CXL at the veterinary clinical teaching
hospital of the Veterinary (Vetsuisse) Faculty of the Uni-
versity of Zurich, Switzerland.
Pretreatment and post-treatment examinations
Both patients underwent slit-lamp examination (SL 15;
Kowa Company Ltd.3 ), fluorescein staining (Fluorescein
Sodium; Acrivet 4), Schirmer tear testing (Schirmer Tear
Test; Intervet/Schering-Plough Animal Health), tonome-
try (TonoVet; ICare 5), indirect ophthalmoscopy (Omega
500, Heine 2.2 PanRetinal and 28D lenses; Volk 6) and
photographic documentation (Nikon D90 camera and Ni-
kon AF Micro Nikkor 60 mm lens; Nikon Corp. 7) at the
initial visit. Slit-lamp examination, fluorescein staining and
photographic documentation were performed during all
follow-up visits. Corneal thickness measurements were
performed only on patient 2 during the baseline examina-
tion, during the CXL procedure and at each recheck
appointment. The corneal thickness measurements before
and after CXL and at the first two timepoints during the
CXL procedure were obtained via high-resolution ultra-
sound (40 MHz probe, Eyecubed I-3 System, version 4;
Ellex 8). Corneal thickness was measured from each of the
B-scan images using the ultrasound unit’s internal calli-
pers. The measurements at the second through eighth
timepoint during the CXL procedure were taken with an
ultrasound pachymeter (PachPen handheld ultrasound
pachymeter; Accutome 9). The second measurement during
the CXL procedure was taken with both modalities with
<40 lm difference between measurements. All pachymetry
measurements were averaged (2–4 measurements per time-
point). Total follow-up was 17.5 months for case 1 and
6 months for case 2.
Patients
Patient 1, a 13-year-old male neutered Shepherd mix, had
been diagnosed with anterior uveitis in both eyes (OU) 10by
the referring veterinarian 2 months prior to referral. A
Rickettsia coronii infection was the presumed aetiology
and treatment with systemic doxycycline (Supracyclin,
Grunenthal, 10 mg/kg orally twice daily for 3 weeks) and
topical prednisolone acetate 1% (Pred Forte; Allergan 11)
and diclofenac 0.1% (Voltaren, Novartis 12) was started at
this time. Complete ophthalmic examination at the veteri-
nary clinical teaching hospital of the Veterinary (Vetsuisse)
Faculty of the University of Zurich, Switzerland, revealed
diffuse, noncystic corneal oedema, central epithelial ero-
sions, mild inferotemporal corneal neovascularization and
blepharospasm. Menace responses, dazzle and pupillary
light reflexes were present OU and no signs of an active
uveitis were observed. An IOP 13of 7 mmHg was measured
in the left eye (OS) 14; 15and 8 mmHg in the right eye (OD).
Schirmer tear test measurements were within normal lim-
its at all measured timepoints. A fundic examination was
severely limited by the lack of corneal transparency and
patient cooperation. Oral doxycycline was continued and
topical neomycin/polymyxin/bacitracin ointment (Oph-
thalmyvet, Vetoquinol) was started three times daily OU.
During the 2 months following this visit, the patient was
repeatedly seen by an ECVO Diplomate in private prac-
tice (LWR), who confirmed the diagnosis of endothelial
decompensation and absence of active uveitis. During this
period, the patient was treated twice with cotton tip appli-
© 2013 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 1–6
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cator and diamond burr (Algerbrush II; The Alger Com-
pany, Inc.16 ) debridement and bandage contact lens place-
ment (Acrivet Pat D2, Acrivet). Following these
treatments, the patient was comfortable with the contact
lenses in place, but discomfort returned due to the pres-
ence of persistent corneal erosions as soon as the contact
lenses were removed. Treatment with topical broad spec-
trum antibiotics was continued throughout the treatment
period.
The patient was again referred to the Veterinary
(Vetsuisse) Faculty of the University of Zurich, Switzerland,
for CXL treatment OU. Microcystic corneal oedema,
corneal epithelial bullae and erosions, mild to moderate in-
ferotemporal corneal neovascularization and pigmentation
and multifocal depigmentation of the nictitating membrane
were observed OU (Fig. 1a). CXL was performed OU
under general anaesthesia as previously described.13 A ban-
dage contact lens (Acrivet Pat D2, Acrivet) was placed OU
immediately after CXL. Treatment was started with topical
ofloxacin (Floxal, Bausch & Lomb17 ) eye drops three times
daily OU and oral tramadol (Tramadol Mepha; Mepha
Pharma AG18 ) at 3–5 mg/kg up to three times daily as needed
for pain. The patient was discharged from the clinic on the
day of the procedure. Via telephone follow-up the next day,
the owner reported conjunctival redness and intermittent
blepharospasm, which resolved during exercise.
Both eyes were comfortable and both contact lenses
were removed (LWR) 1 week after the CXL procedure.
The corneas were both fluorescein negative.
Two weeks after the CXL procedure, both corneas were
comfortable, subjectively less oedematous and fluorescein
negative with a smooth epithelial surface. The corneal
neovascularization and pigmentation and the depigmenta-
tion of the nictitating membrane were unchanged and
interpreted as being consistent with pre-existent chronic
superficial keratitis. Topical treatment was started with
cyclosporine 0.2% (Optimmune, Intervet 19) three times
daily and neomycin/polymyxin/dexamethasone 0.1%
(Maxitrol, Alcon 20) four times daily OU. These medications
were to be tapered to twice daily OU over 8 weeks. At
recheck, 2 months later, both corneas remained comfort-
able and fluorescein negative with a smooth epithelial sur-
face (Fig. 1b). The corneal and nictitating membrane
pigmentation were unchanged and the corneal neovascu-
larization had completely regressed OU. Treatment with
cyclosporine 0.2% was continued twice daily and neomy-
cin/polymyxin/dexamethasone 0.1% was tapered and dis-
continued over a 3 month period of time. The owner
reported an improvement in visual performance at the
3- and 5-month postprocedure rechecks. At 6.5 months
after the CXL procedure, the owner reported decreased
corneal transparency and deterioration of visual perfor-
(a)
(d)
(b) (c)
(e)
Figure 1. Clinical effect of Corneal collagen cross-linking (CXL) on bullous keratopathy (two patients). Bullous keratopathy as a result of
endothelial decompensation was diagnosed in both patients. The appearance OD of case 1 immediately prior to CXL (a). The appearance OS
was identical to OD. Note the dense microcystic corneal oedema and epithelial erosion. Fine pigmentation accompanied the neovascularization
advancing towards the centre of the cornea (a). The appearance OD 2 (b) and 15 (c) months post-CXL. Both eyes were comfortable with a
smooth, fluorescein-negative corneal surface and subjectively less intense corneal oedema. Minimal progression of the pigmentation was present.
The appearance of case 2 immediately prior to CXL (d). Note the dense microcystic corneal oedema OU and the irregularity of the corneal
surface (OS > OD). A central epithelial erosion was present OU. Radially oriented areas of pigmentation OD and neovascularization OS were
present. One week post-CXL, both eyes were comfortable with a smooth, fluorescein-negative corneal surface and less intense corneal oedema (e).
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mance, which were both difficult to confirm clinically.
Topical treatment with 5% sodium chloride ointment
(Muro 128, Bausch & Lomb) 3–4 times daily OU was
added to the cyclosporine treatment. During the rest of
the follow-up period up to a recheck at 17.5 months after
the CXL procedure, no further changes were observed
(Fig. 1c). Due to mild local irritation, application of the
5% sodium chloride ointment was tapered to twice daily
OU.
Patient 2, a 14-year-old female castrated Jack Russell
Terrier, presented with dense corneal oedema OS and mild
to moderate corneal oedema OD. The corneal surface was
irregular OU with faint multifocal fluorescein staining OS
and a small epithelial erosion OD. Schirmer tear test mea-
surements were within normal limits at all measured time-
points. Corneal thickness was 0.97 mm OD and 1.28 mm
OS as measured by high-resolution ultrasound. A complete
examination of the anterior chamber was not possible due
to the loss of corneal transparency. The iris seemed slightly
hyperpigmented. However, no signs of an active uveitis
were observed. The patient was diagnosed with corneal
endothelial decompensation, which was presumed to be
age-related or uveitis-induced based on the iris hyperpig-
mentation and low IOPs of 3 mmHg OS and 4 mmHg OD
that were measured. Topical treatment was started with 5%
sodium chloride ointment four times daily OU. Topical
anti-inflammatory treatment was postponed due to the
observed corneal surface abnormalities and a follow-up
examination was recommended 2 weeks later.
The patient then presented 2 months later with a his-
tory of intermittent blepharospasm since the previous visit.
No change was observed with the use of 5% sodium chlo-
ride ointment, and the episodes of blepharospasm were
increase in length and frequency. Ophthalmic examination
revealed dense microcystic corneal oedema, irregularity of
the corneal surface, central epithelial erosions OU, radially
oriented areas of pigmentation OD and neovascularization
OS (Fig. 1d). Corneal thickness had increased to 1.2 mm
OD and 1.43 mm OS.
Corneal collagen cross-linking was performed OU
under general anaesthesia as previously described.13 Both
corneas of the second patient were dehydrated to a corneal
thickness of approximately 400 lm using topical 70%
glycerol solution immediately prior to CXL according to
a previously published protocol.18 This was carried out to
increase the proportion of total stromal thickness reached
by CXL, which has a penetration limit of  300 lm.1
Treatment with 5% sodium chloride ointment three times
daily was continued and topical neomycin/polymyxin/baci-
tracin ointment four times daily OU, oral tramadol
3–5 mg/kg up to three times daily as needed and robenac-
oxib (Onsior, Novartis) 1 mg/kg once daily with food for
3 days were started. Contact lenses were not placed and
the patient was discharged from the clinic on the day of
the procedure.
One week after the CXL procedure, both eyes were
comfortable and fluorescein negative with a dense micro-
cystic corneal oedema and smooth corneal surface
(Fig. 1e). According to the owner, there was no improve-
ment in vision. Corneal thickness was 1.06 mm OD and
1.2 mm OS. A demarcation line was visible on ultrasound
between the anterior third and posterior two-thirds of the
stroma (Fig. 2a). Only topical treatment with 5% sodium
chloride ointment three times daily was continued. Apart
from mild progression of pigmentation OD and neovascu-
larization OS, the clinical situation at 1 month after the
(a) (b)
Figure 2. Corneal pachymetry data at various timepoints before, during and after Corneal collagen cross-linking (CXL) (patient 2). High-
resolution ultrasound (HRUS) image of the central cornea and anterior lens capsule (white arrow) OS of case 2 taken 1 week after CXL (a).
A demarcation line was visible between the anterior third and posterior two-thirds of the corneal stroma. The anterior stroma (asterisk) was
hyperechogenic compared to the posterior stroma. Digital callipers were used for corneal thickness measurements (yellow line). Corneal
thickness of case 2 in lm plotted over time (b). An increase in corneal thickness between the first presentation and the presentation immediately
prior to CXL had been observed. The decrease in corneal thickness measured during the CXL procedure was caused by the riboflavin–dextran
20% (decrease between first and second measurement) and glycerol 70% solutions (residual decrease). Four months after CXL, the corneal
thickness had returned to the values measured immediately prior to CXL.
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CXL procedure was identical to the corneal appearance
1 week postprocedure. Corneal thickness was 0.94 mm
OD and 1.28 mm OS. Topical treatment with 5% sodium
chloride ointment three times daily OU was continued
and topical treatment with cyclosporine 0.2% and ketoro-
lac 0.5% (Acular, Allergan) twice daily OU was initiated.
During the remainder of the follow-up period at 6 months
after the CXL procedure, no further changes in visual per-
formance, patient comfort or clinical appearance of the
corneas were observed. At the 4-month recheck, corneal
thickness was 1.2 mm OD and 1.46 mm OS. However,
topical treatment with 5% sodium chloride ointment was
discontinued due to irritation. Topical treatment was con-
tinued with cyclosporine 0.2% twice daily and ketorolac
0.5% once daily.
RESULTS AND DISCUSSION
All four eyes included in this case report had persistent/
recurrent corneal epithelial erosions present for at least
2 months prior to CXL treatment. These four eyes were
comfortable and fluorescein negative 1 week following
CXL treatment and remained so for the rest of the fol-
low-up period: 17.5 months for case 1 and 6 months for
case 2. No adverse effects of the CXL procedure, such as
delayed epithelial healing, postprocedural pain or infection
were observed. Pigmentation of the cornea was present
prior to CXL in both patients and appeared to have pro-
gressed slightly 1 month after CXL in the second patient.
Further progression of the corneal pigmentation was not
observed in either patient while being treated with cyclo-
sporine 0.2% twice daily OU.
The primary treatment goal, namely resolution of the
corneal erosions and associated pain, was fulfilled, indicat-
ing that CXL may be a successful treatment alternative for
dogs with bullous keratopathy. This result is consistent
with the current literature, as various case series reported
the effective use of CXL for the treatment of corneal
oedema, endothelial decompensation and bullous keratop-
athy in humans.11,18–22
Corneal collagen cross-linking seems to have led to a
subjective increase in corneal transparency in case 1 and
to an objective, although not clinically significant, thin-
ning of the cornea in case 2. The effect was temporary in
both cases, which is consistent with the current clinical
physician-based ophthalmic literature.11,21–23
Wollensak et al.24 described a significant decrease in the
swelling of the anterior corneal stroma after CXL in in vi-
tro pig eyes. A study by Sondergaard et al.3 demonstrated
a significant reduction in anterior stromal swelling pres-
sure in porcine and human corneas after CXL in vitro,
suggesting that CXL may reduce corneal swelling pressure
in vivo as well, thereby reducing oedema and improving
vision. The mechanism of this CXL-induced swelling
pressure reduction is unknown. However, cross-linking
between corneal collagen fibres has not been demonstrated
after CXL, and it seems unlikely that the effects of CXL
are limited to stromal collagen alone.25 Hayes et al.2 con-
cluded that cross-links formed during riboflavin/UVA
therapy likely occur at the collagen fibril surface and in
the proteoglycan network surrounding the collagen fibres.
Furthermore, swelling pressure reducing effects of CXL
might also be mediated through modifying effects on the
hydrophilic and negatively charged nature of the stromal
glycosaminoglycans.25,26 No convincing explanations
regarding the temporary thinning effect of CXL on the
cornea have been proposed in the scientific literature.
Current CXL protocols deliver the cross-linking effects
to the superficial stroma 1,24,27 where the swelling poten-
tial is the lowest.28,29 The dehydration of both corneas of
case 2 with topical 70% glycerol solution immediately
prior to CXL did not change the outcome compared to
case 1 in terms of resolution of the erosions and associated
pain nor in terms of corneal transparency and rehabilita-
tion of vision. Finding ways to treat the posterior stroma
and thereby preventing posterior corneal stromal swelling
could potentially increase the effectiveness of CXL.
Corneal collagen cross-linking is less invasive compared
to some of the surgical alternatives for the symptomatic
treatment of bullous keratopathy in dogs such as thermo-
keratoplasty and conjunctival flap surgery, which cause
significant anterior stromal and corneal surface fibrosis.12,17
If any conclusions can be drawn based on the two cases
presented in this manuscript, it would be that currently
the main indication for CXL treatment of bullous kera-
topathy in dogs is the treatment of persistent corneal
oedema-induced epithelial erosions. The temporary and
clinically insignificant decrease in corneal thickness does
not justify the use of CXL for the sole purpose of increas-
ing corneal transparency and improving vision. However,
the presently used CXL protocols were developed for the
treatment of progressive keratoconus in humans with a
focus on treatment safety.1 These protocols will likely
need modification regarding CXL intensity and riboflavin
concentration to fit both the dog cornea and to optimize
the treatment of bullous keratopathy.
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